Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
950200.KQ
SellSinkerPsomagen, Inc. · Healthcare · United States · $50M · Avg Vol: $2M/d
24
StockRankGet insider-trade alerts
Q
44
V
32
M
35
P/E (TTM)
—
ROE
-10.4%
D/E
0.6x
Dividend %
—
COMPANY DESCRIPTION
Psomagen, Inc. engages in the provision omics solutions and contract laboratory services. The company's research services includes genomics, a study of gene sequence and expression; epigenomics, a study of epigenetic changes, such as chromatin assembly, histone modification, and DNA-protein...
FINANCIAL SUMMARY (KRW)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 43.4B | 32.3B | 43.7B | 59.2B | 10.9% | 59.4B |
| EPS (KRW) | -52.00 | -222.00 | -286.00 | -156.00 | — | — |
| Shares | 19.2M | 19.2M | 19.2M | 19.2M | +0.2% | 19.2M |
| Debt | 5.2B | 5.0B | 11.3B | 13.2B | 36.6% | 14.7B |
| Equity | 35.7B | 32.2B | 30.8B | 27.3B | -8.5% | — |
| Op CF | -288.7M | 1.6B | 3.3B | 834.4M | -27.5% | -464.0M |
| Inv CF | -3.0B | -12.6B | -2.1B | 2.5B | — | — |
| Fin CF | -2.8B | -1.1B | -79.4M | 448.6M | — | — |
Loading 1Y...
PRICE (1Y)+18.5%
SMA 50SMA 200
Close
$2.37
RSI (14)
30.4
52W High
$3.49
From 52W High
0.7%
SCORE BREAKDOWN
Quality
44
ROIC
-8.7%35.8
ROE
-10.4%34.6
GP/Assets
31.2%65.9
Op. Margin
-5.6%29.4
FCF/Assets
-2.7%39.2
Piotroski
783.9
Int. Cover
-3.2x29.4
D/E Ratio
0.57x26.3
Current Ratio
1.59x29.0
Value
32
P/E (TTM)
—N/A
EV/EBITDA
21.3x32.2
P/FCF
—N/A
P/B
—N/A
P/S
1.1x81.5
Div Yield
—N/A
Momentum
35
52W High %
68%47.4
RS 6M
-30%28.8
SMA 50/200
0.90x32.4
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$50M
P/E (Forward)
—
Gross Margin
25.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 950200.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 950200.KQ | Psomagen, Inc.(you) | $50M | 24 | Sell |
| 950130.KQ | Access Bio, Inc. | $65M | 13 | Strong Sell |
| PRPO | Precipio, Inc. | $52M | 47 | Hold |
| XGN | Exagen Inc. | $179M | 28 | Sell |
| MYGN | Myriad Genetics, Inc. | $302M | 21 | Sell |
| BDSX | Biodesix, Inc. | $283M | 29 | Sell |
| IMDX | Insight Molecular Diagnostics Inc. | $135M | 3 | Strong Sell |
| FLGT | Fulgent Genetics, Inc. | $540M | 45 | Hold |
| PSNL | Personalis, Inc. | $1.8B | 24 | Sell |
| CSTL | Castle Biosciences, Inc. | $1.0B | 39 | Hold |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%